Analyst Reco. I-Mab BOERSE MUENCHEN

Equities

0VY

US44975P1030

Real-time BOERSE MUENCHEN Other stock markets 15:14:17 2024-06-27 EDT			5-day change	1st Jan Change
1.58 ^EUR	-2.47%		-2.41%	-2.99%

06-06	I-Mab Appoints Phillip Dennis as Chief Medical Officer	CI
06-05	I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating	03-18	MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating	03-15	MT
Needham Trims I-Mab Price Target to $23 From $24, Maintains Buy Rating	23-09-25	MT
HC Wainwright Adjusts Price Target on I-Mab to $18 From $25, Maintains Buy Rating	23-08-18	MT
Needham Lowers Price Target on I-Mab to $24 From $33, Maintains Buy Rating	23-04-03	MT
Piper Sandler Adjusts Price Target on I-Mab to $25 From $30, Maintains Overweight Rating	23-04-03	MT
HC Wainwright Adjusts Price Target on I-Mab to $25 From $45, Maintains Buy Rating	23-04-03	MT
I-Mab Says Combination Treatment for Myelodysplastic Syndrome Showed Overall Response Rate of 86.7% in Phase 2 Trial	22-09-12	MT
HC Wainwright Adjusts I-Mab's Price Target to $45 From $70, Maintains Buy Rating	22-08-31	MT
Needham Adjusts I-Mab's Price Target to $33 From $41, Reiterates Buy Rating	22-08-31	MT
Piper Sandler Adjusts I-Mab's Price Target to $30 From $35, Reiterates Overweight Rating	22-08-31	MT
Needham Lowers I-Mab's Price Target to $41 From $72, Maintains Buy Rating	22-08-17	MT
HC Wainwright Adjusts I-Mab's Price Target to $70 From $80, Keeps Buy Rating	22-05-31	MT
Piper Sandler Adjusts I-Mab's Price Target to $35 From $80, Reiterates Overweight Rating	22-05-31	MT
Needham Adjusts I-Mab's Price Target to $72 From $85, Reiterates Buy Rating	22-05-31	MT
HC Wainwright Adjusts I-Mab's Price Target to $80 from $95, Keeps Buy Rating	22-03-30	MT
Piper Sandler Adjusts I-Mab's Price Target to $80 From $90, Reiterates Overweight Rating	22-03-30	MT
SWS Research Starts I-Mab at Buy with $96 Price Target	21-12-09	MT
Needham Adjusts Price Target on I-Mab to $85 from $83, Keeps Buy Rating	21-11-01	MT
I MAB : HC Wainwright Adjusts I-Mab's Price Target to $95 from $75, Keeps Buy Rating	21-09-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. I-Mab BOERSE MUENCHEN

Equities

0VY

US44975P1030

Analyst Reco.

Filters